Search

Your search keyword '"Bucher, Brigitte"' showing total 7 results
Start Over Author "Bucher, Brigitte" Language english
7 results on '"Bucher, Brigitte"'

1. Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022): Updated statement of the Austrian Society of Pneumology (ASP)

Author

Olschewski, Horst, Eber, Ernst, Bucher, Brigitte, Hackner, Klaus, Handzhiev, Sabin, Hoetzenecker, Konrad, Idzko, Marco, Klepetko, Walter, Kovacs, Gabor, Lamprecht, Bernd, Löffler-Ragg, Judith, Meilinger, Michael, Müller, Alexander, Prior, Christian, Schindler, Otmar, Täubl, Helmut, Zacharasiewicz, Angela, Zwick, Ralf Harun, Arns, Britt-Madelaine, Bolitschek, Josef, Cima, Katharina, Gingrich, Elisabeth, Hochmair, Maximilian, Horak, Fritz, Jaksch, Peter, Kropfmüller, Roland, Pfleger, Andreas, Puchner, Bernhard, Puelacher, Christoph, Rodriguez, Patricia, Salzer, Helmut J. F., Schenk, Peter, Stelzmüller, Ingrid, Strenger, Volker, Urban, Matthias, Wagner, Marlies, Wimberger, Franz, and Flick, Holger

Published
2022
Full Text
View/download PDF

2. Management of patients with SARS-CoV-2 infections and of patients with chronic lung diseases during the COVID-19 pandemic (as of 9 May 2020): Statement of the Austrian Society of Pneumology (ASP)

Author

Flick, Holger, Arns, Britt-Madelaine, Bolitschek, Josef, Bucher, Brigitte, Cima, Katharina, Gingrich, Elisabeth, Handzhiev, Sabin, Hochmair, Maximilian, Horak, Fritz, Idzko, Marco, Jaksch, Peter, Kovacs, Gabor, Kropfmüller, Roland, Lamprecht, Bernd, Löffler-Ragg, Judith, Meilinger, Michael, Olschewski, Horst, Pfleger, Andreas, Puchner, Bernhard, Puelacher, Christoph, Prior, Christian, Rodriguez, Patricia, Salzer, Helmut, Schenk, Peter, Schindler, Otmar, Stelzmüller, Ingrid, Strenger, Volker, Täubl, Helmut, Urban, Matthias, Wagner, Marlies, Wimberger, Franz, Zacharasiewicz, Angela, Zwick, Ralf Harun, and Eber, Ernst

Published
2020
Full Text
View/download PDF

7. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.

Author

Ruttmann E, Geltner C, Bucher B, Ulmer H, Höfer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, and Müller LC

Subjects
Adult, Cytomegalovirus Infections immunology, Drug Therapy, Combination, Female, Humans, Immunoglobulins, Intravenous, Male, Middle Aged, Retrospective Studies, Antiviral Agents therapeutic use, Bronchiolitis Obliterans prevention & control, Cytomegalovirus Infections prevention & control, Ganciclovir therapeutic use, Immunization, Passive, Immunoglobulins therapeutic use, Lung Transplantation adverse effects
Abstract

Background: The benefit of cytomegalovirus (CMV) hyperimmune globuline in preventing CMV infection after lung transplantation still remains unclear. The aim of this study was to investigate the effect of combined prophylaxis using ganciclovir (GAN) and CMV hyperimmune globulin (CMV-IG) on CMV infection, CMV disease, survival and its role in preventing Bronchiolitis obliterans syndrome (BOS)., Methods: A consecutive series of 68 CMV high-risk lung transplant recipients (D+/R-, D+/R+), who had a minimum follow-up of 1 year posttransplant were analyzed. Thirty patients (44.1%) received single GAN prophylaxis for 3 months (control group) and 38 recipients (55.9%) received GAN together with CMV-IG 7 times during the first postoperative month (study group). Median follow-up was 16.5 months in the control and 23.8 months in the study group (P = 0.54)., Results: Five CMV-related deaths (16.7%) occurred in the control group (P = 0.014). Fifteen recipients suffered from CMV pneumonitis and three patients had CMV syndrome. In the control group, 13 recipients (43.3%) suffered from clinically manifested CMV disease compared to 5 (13.2%) in the study group (P = 0.007). Additionally, recipient survival was significantly better in the study group (P = 0.01). One year freedom from CMV affection was 52.1% in the control and 71.5% in the study group (P = 0.027). Three-year freedom from BOS was significantly higher in the study group (54.3% vs. 82%, P = 0.024)., Conclusions: In CMV high risk patients, additional CMV-IG administration seems to be effective to reduce CMV-related morbidity and to avoid CMV-related mortality. Reduced incidence of BOS may result from improved CMV prevention, although randomized trials are warranted.

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results